CALL FOR ABSTRACT SUBMISSIONS

New in 2018: This year the Scientific Programme Committee plans to organize a Contributed Papers section and a Poster section within the Forum. The organizers are pleased to invite authors to submit abstracts for poster and oral symposium presentations to be delivered at the 3rd Annual Biosimilars Forum. Abstract proposals for both sessions are awaited.
Abstract Submission Deadline: 10th SEPTEMBER, 2018

SUGGESTED TOPICS OF SUBMISSION (but not limited to)

  • Problems related to quality analysis
  • Multiple endpoints in biosimilar studies
  • The choice of equivalence margins
  • Subgroup analysis
  • Interchangeability
  • Switchability
  • Other topics in harmony with the Forum’s professional programme are also welcome

Email us your Abstract in 250 words at the maximum, participate at the 3rd Biosimilars Forum with your professional work:

By submitting your Abstract, you’re agreeing to accept our Author Agreement Rules (see below)

Questions? 
Send related correspondence and questions regarding abstract submissions or notifications to event@accelsiors.com.

ABOUT THE FORUM

Conference Theme:
Statistical and Regulatory Perspectives in Bio- and Nanosimilar Development

This three-day series of events consists of a COURSE DAY with two professional lecture sessions (October 25th), a SYMPOSIUM DAY (invited presentations, posters and round table session, scheduled for October 26th) and a SEMINARIUM DAY (lectured by special experts from the field of nanotechnology-formulated drug development – October 27th).

The Forum offers a dedicated overview and informative discussion on today’s most relevant issues and challenges in Biosimilar research and nanomedicine development with the participation of leading experts from the fields of regulatory, academic and clinical research.

SCIENTIFIC PROGRAMME COMMITTEE

Ildikó ARADI 
Vice-Chair, Medicines for Europe, Biosimilar Medicines Group; Head of Clinical Development of Biologics, Gedeon Richter Plc.

Bernd JILMA 
Vice Chair, Department Clinical Pharmacology, Medical University of Vienna

Franz KÖNIG 
Associate Professor, Section for Medical Statistics, Medical Unversity of Vienna

Stephan LEHR 
Statistician, Austrian Medicines and Medical Devices Agency; President, Viennese Section of IBS

Júlia SINGER 
Chief Scientific Officer, Accelsiors CRO Ltd.; President, Hungarian Society for Clinical Biostatistics

Heike WOEHLING
Director Biostatistics for Biostatistics Biosimilars, Analytics group, Novartis

The unique specialty of this event series is that it brings together regulators, medical scientists, clinical researchers and pharmaceutical development companies from around the world to provide an opportunity for networking and constructive dialogue related to the specific challenges of biosimilar development.

THE FORUM WILL BE COMPOSED OF SEVERAL TYPES OF CONTRIBUTIONS

Contributed Oral Presentation

These might review recent research literature pertaining to a particular problem or approach, indicate what the findings suggest, and/or provide a suggestion – with rationale and justification – for a different approach or perspective on that problem. Reflection papers might also analyze general trends or discuss important issues in topics related to Biosimilars. (15 minutes).

Posters / Demonstrations

These have one page at the maximum (poster size will be discussed) besides the poster itself (or demonstration) that will be exposed at the conference.

Invited Talks

These will be made of contributions from well-known experts of biosimilar drug development and pharmaceutical industry representatives.

AUTHOR AGGREEMENT RULES

By submitting the abstract, the author confirms and agrees to the following:

  • Abstracts will be reviewed by the Scientific Programme Committee of the event, and accepted submissions will be presented in the conference.

  • Please note that all fields at the email must be completed for the abstract (title, data and contact information of author / co-authors, …) to be considered by the review committee.
      • Objective, problem under investigation, hypothesis, or research goal
      • Description of research methods
      • Summary of findings
      • Statement of how the research advances the Biosimilar drug development field
  • All authors approve submitting this work for presentation
  • The authors have done the work reported in the abstract and take full responsibility for the contents
  • The authors transfer all copyright ownership of the abstract to the 3rd Annual Biosimilars Forum
  • The authors agree to confine their presentation to information in the abstract
  • At least one author will be available to present the abstract if selected for the program
  • The author will immediately notify the Scientific Programme Committee of the Forum if they are unable to make a presentation or if the presenting author must be changed
  • The authors guarantee that clinical studies and any animal tests have proceeded with the official permission from the proper authorities
  • Delegates wishing to submit an abstract for the 3rd Annual Biosimilars Forum must register for the conference.
  • Delegates with accepted submissions are eligible to attend at the Forum for Early Bird ticket rates (up to 25% discount from the regular registration prices)